The United Kingdom and the United States have secured a landmark bilateral deal that will ensure no tariffs on UK drug products being sold in the US market.
Agreement Details of the Accord
As part of the deal, the UK has agreed to boost expenditure on drugs through the NHS. This pledge ensures that duties on these crucial exports will be held at nothing for a period of three years.
This deal comes after earlier statements to significantly raise duties on branded pharmaceutical imports, with potential rates floated up to double the cost.
"This deal between the Britain strengthens the international landscape for innovative medicines and establishes long-overdue fairness to transatlantic drug exports," a release said.
Economic Importance
Medicines are one of the Britain's biggest goods shipped to the United States, which is clearly the largest market for major companies like GSK and AstraZeneca.
Trade data reveal that in the 12 months prior to last September, the UK exported drugs totaling £11.1bn to the US. This figure accounted for a significant portion of British export trade in that period.
"This guarantee protects work, stimulates investment and facilitates the UK to become a international leader for life sciences," the Business and Trade Secretary commented.
Detailed NHS Changes
The agreement includes several notable pledges from the British government:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it considers new medicines to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a goal to raise overall health service expenditure on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The percentage manufacturers must return to the NHS to prevent overspending will be capped at fifteen percent. Last year, refunds were more than 20%.
Broader Context
The pact takes place against a protracted tension between the drug companies and the ministers over drug pricing and regulatory access.
These tensions were intensified by arguments that American patients were paying a premium for the equivalent treatments than consumers in the UK and Europe.
Over the last 18 months, several significant drug company projects in the UK have been paused or cancelled, while major investments have been pledged toward US facilities.
One official publicly accepted that the NHS must invest a greater share on medicines, noting that its budget allocation on drugs had decreased as a proportion of its total funding over the last ten years.
